Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan AA, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS. Walterhouse DO, et al. Among authors: hayes jordan aa. J Clin Oncol. 2014 Nov 1;32(31):3547-52. doi: 10.1200/JCO.2014.55.6787. Epub 2014 Sep 29. J Clin Oncol. 2014. PMID: 25267746 Free PMC article. Clinical Trial.
Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.
Walterhouse DO, Meza JL, Breneman JC, Donaldson SS, Hayes-Jordan A, Pappo AS, Arndt C, Raney RB, Meyer WH, Hawkins DS. Walterhouse DO, et al. Pediatr Blood Cancer. 2011 Jul 15;57(1):76-83. doi: 10.1002/pbc.22928. Epub 2011 Feb 4. Pediatr Blood Cancer. 2011. PMID: 21298768 Free PMC article. Clinical Trial.
Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan A, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS. Walterhouse DO, et al. Cancer. 2017 Jun 15;123(12):2368-2375. doi: 10.1002/cncr.30613. Epub 2017 Feb 17. Cancer. 2017. PMID: 28211936 Free PMC article.
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden S, Yock TI, Meyer WH. Hawkins DS, et al. J Clin Oncol. 2018 Sep 20;36(27):2770-2777. doi: 10.1200/JCO.2018.77.9694. Epub 2018 Aug 9. J Clin Oncol. 2018. PMID: 30091945 Free PMC article. Clinical Trial.
A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL, Million L, Chi YY, Anderson J, Tian J, Hibbitts E, Coffin C, McCarville MB, Randall RL, Parham DM, Black JO, Kao SC, Hayes-Jordan A, Wolden S, Laurie F, Speights R, Kawashima E, Skapek SX, Meyer W, Pappo AS, Hawkins DS. Spunt SL, et al. Lancet Oncol. 2020 Jan;21(1):145-161. doi: 10.1016/S1470-2045(19)30672-2. Epub 2019 Nov 27. Lancet Oncol. 2020. PMID: 31786124 Free PMC article.
45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Ermoian RP, Breneman J, Walterhouse DO, Chi YY, Meza J, Anderson J, Hawkins DS, Hayes-Jordan AA, Parham DM, Yock TI, Donaldson SS, Wolden SL. Ermoian RP, et al. Among authors: hayes jordan aa. Pediatr Blood Cancer. 2017 Sep;64(9):10.1002/pbc.26540. doi: 10.1002/pbc.26540. Epub 2017 May 26. Pediatr Blood Cancer. 2017. PMID: 28548706 Free PMC article. Clinical Trial.
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH. Arndt CA, et al. J Clin Oncol. 2009 Nov 1;27(31):5182-8. doi: 10.1200/JCO.2009.22.3768. Epub 2009 Sep 21. J Clin Oncol. 2009. PMID: 19770373 Free PMC article. Clinical Trial.
Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Skapek SX, Hayes-Jordan AA, Donaldson SS, Brown KL, Triche TJ, Meyer WH, Hawkins DS. Rodeberg DA, et al. J Clin Oncol. 2011 Apr 1;29(10):1304-11. doi: 10.1200/JCO.2010.29.4611. Epub 2011 Feb 28. J Clin Oncol. 2011. PMID: 21357792 Free PMC article. Clinical Trial.
141 results